Literature DB >> 17497342

Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters.

Robert Irzmański1, Maciej Banach, Mariusz Piechota, Jan Kowalski, Marcin Barylski, Czesław Cierniewski, Lucjan Pawlicki.   

Abstract

INTRODUCTION: The aim of the work was to study the maintenance of atrial and brain natriuretic peptide (ANP, BNP) and endothelin-1 (ET-1) in patients with idiopathic arterial hypertension and the relationships between cardiac morphological parameters and concentrations of examined peptides in group of patients with left ventricular hypertrophy (LVH).
METHODS: Seventy-six patients were enrolled in the study: 21 patients with confirmed idiopathic arterial hypertension (group 1), 18 with idiopathic hypertension and eccentric hypertrophy (group 1a), 14 with idiopathic hypertension and concentric hypertrophy (group 1b), and 23 patients without arterial hypertension, organic heart disease, or chronic respiratory tract diseases (group 2 - control group). All subjects were submitted for echocardiographic evaluation. Posterior wall thickness (PWT), interventricular septum thickness (IVST), left ventricular end-diastolic diameter (LVEDd), left atrium diameter (LAD), left ventricular mass index (LVMI), ejection fraction (EF), fractional shortening (FS), midwall shortening fraction (MWS), and relative wall thickness index (RWT) were studied. Concentrations of ANP(1-28), BNP, and ET-1 were determined with the use of radioimmunological kits (RIA). The obtained results were subjected to statistical analysis.
RESULTS: A considerable increase of ANP and BNP was observed in all patients with hypertension (group 1) in comparison to patients without hypertension (group 2). Significant increases of ANP were found in groups 1a and 1b in comparison to group 1 and 2, as well as considerably increase of BNP in group 1b compared to groups 1, 1a, and 2. In the group of patients with hypertension (group 1), a significant increase in the concentration of ET-1 compared to group 2 was found. However, the concentrations of ET-1 in groups 1 and 2 were not statistically different. Significant differences in concentrations of ET-1 between groups 1a, 1b, and 1 and 2 were seen. Significant correlations were found between concentrations of ANP, BNP, ET-1 and morphological parameters: PWT, IVST, LVMI and RWT. In group 1b, a correlation between concentrations of ANP, BNP, MWS, and LAD was found. The multiple regression analysis showed that RWT independently correlates with concentrations of ANP and BNP, and the concentration of BNP is in closer relation to RWT than ANP. In the case of ET-1, the multiple regression analysis did not show that LVMI or RWT had any independent influence on secretion of ET-1 in patients with idiopathic hypertension and LVH.
CONCLUSIONS: Increased concentration of ANP in patients with idiopathic hypertension may point to the coexistence of complications with type of LVH. High concentration of BNP may specifically suggest concentric LVH. This is important - especially if there are difficulties in interpretations of results of other clinical examinations. However, increased concentrations of ET-1 in the plasma of patients with hypertension and LVH should not be treated as an indicator of LVH degree.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497342     DOI: 10.1080/10641960701361593

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  8 in total

Review 1.  Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world.

Authors:  Dike Ojji; Elena Libhaber; Kim Lamont; Friedrich Thienemann; Karen Sliwa
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

2.  Plasma C-terminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension.

Authors:  M A Al-Omari; M Khaleghi; T H Mosley; N G Morgenthaler; J Struck; A Bergmann; I J Kullo
Journal:  J Hum Hypertens       Date:  2010-02-25       Impact factor: 3.012

3.  Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.

Authors:  Andreia Biolo; Sujata Ramamurthy; Lawreen H Connors; Carl J O'Hara; Hans K Meier-Ewert; Pamela T Soo Hoo; Douglas B Sawyer; David C Seldin; David S Seldin; Flora Sam
Journal:  Circ Heart Fail       Date:  2008-10-14       Impact factor: 8.790

4.  Strong cardiovascular prognostic implication of quantitative left atrial contractile function assessed by cardiac magnetic resonance imaging in patients with chronic hypertension.

Authors:  Matthew Kaminski; Kevin Steel; Michael Jerosch-Herold; Maung Khin; Sui Tsang; Thomas Hauser; Raymond Y Kwong
Journal:  J Cardiovasc Magn Reson       Date:  2011-08-15       Impact factor: 5.364

5.  Lipids, blood pressure, kidney - what was new in 2011?

Authors:  Marcin Barylski; Jolanta Małyszko; Jacek Rysz; Michał Myśliwiec; Maciej Banach
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

6.  The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects.

Authors:  Dike B Ojji; Lionel H Opie; Sandrine Lecour; Lydia Lacerda; Olusoji M Adeyemi; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2014 Sep-Oct       Impact factor: 1.167

7.  N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients.

Authors:  Mariusz Piechota; Maciej Banach; Robert Irzmański; Małgorzata Misztal; Jacek Rysz; Marcin Barylski; Magdalena Piechota-Urbańska; Jan Kowalski; Lucjan Pawlicki
Journal:  Cell Mol Biol Lett       Date:  2006-12-06       Impact factor: 5.787

Review 8.  Natriuretic peptides in cardiovascular diseases.

Authors:  Mariusz Piechota; Maciej Banach; Anna Jacoń; Jacek Rysz
Journal:  Cell Mol Biol Lett       Date:  2008-04-10       Impact factor: 5.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.